Actively Recruiting
Phase 3 Study of Cenerimod Added to Standard Treatment for Adults With Active Lupus Nephritis and Systemic Lupus Erythematosus
Led by Viatris Innovation GmbH · Updated on 2026-07-30
300
Participants Needed
14
Research Sites
26 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying whether cenerimod, when added to regular treatment, helps improve kidney function and is safe for adults with systemic lupus erythematosus SLE and active lupus nephritis. This Phase 3 trial compares cenerimod to a placebo to better understand its effects in this patient group. Participants will take cenerimod or a matching placebo once daily for about 76 weeks approximately 1.5 years, alongside their usual lupus nephritis therapy. The study uses a randomized, double-blind design, with two groups receiving either the active drug or placebo in addition to their background treatment. During the trial, participants will visit the clinic every 1 to 3 months for checkups and tests. Researchers will monitor kidney response and safety by measuring complete renal response at Week 76 and tracking other markers up to that time. The study will assess participants health and kidney function throughout the treatment period.
CONDITIONS
Brief Title
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
Research Team
V
Viatris Innovation Clinical Trial Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
